Company Description
Hemoglobin Oxygen Therapeutics is a biotechnology company focused on the development, manufacture, and commercialization of a proprietary technology platform for oxygen-carrying solutions that address critical unmet medical needs in both human and veterinary medicine.
Using our patents, proprietary technology and know-how, we develop and sell products that, under certain conditions, are a possible alternative to blood transfusions to deliver oxygen to organs and tissues.
Through numerous clinical studies, our products have been shown to address many of the current limitations that exist for blood transfusion.
These include the limited shelf life of blood, logistical challenges of typing/cross-matching, delays in testing for pathogens, and blood shortages during times of high need and/or insufficient donations.
We have significant experience gained through extensive pre-clinical and clinical testing of these products, which have a well-understood and extensively documented safety and efficacy profile.
Management believes that our products are the only hemoglobin-based oxygen carriers (HBOCs) which have received marketing authorizations anywhere in the world.
These products were acquired from OPK Biotech LLC in 2014, which had previously purchased them from Biopure Corporation in 2009.
Our current products are: Hemopure ® for human use; and Oxyglobin® for veterinary use. We are also pursuing a medical device indication for Hemopure under the name ZK1.
ZK1 is intended to act as an additive oxygen carrier solution during ex-vivo, sub-sub normothermic and normothermic machine perfusion of organs to recondition and assess organ viability prior to transplantation.
| Country | United States |
| Founded | 2014 |
| Industry | Health Care |
| Sector | Biotechnology |
| Employees | 10 |
| CEO | Zafiris G. Zafirelis |
Contact Details
Address: 674 Souder Road Souderton, PA 18964 United States | |
| Phone | (267) 382-0064 |
| Website | hbo2therapeutics.com |
Stock Details
| Ticker Symbol | HOTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001615647 |
| Employer ID | 46-5395558 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zafiris G. Zafirelis | Chief Executive Officer, Director |
| Igor Serov | Chief Financial Officer, Director |
| Joseph Rappold, M.D. | Chief Medical Officer |
| Brian Dawson | Senior Director of Process Development |
| Gregory P. Dube, Ph.D. | Senior Director of Pharmacology |
| Melissa Zafirelis | Director of Regulatory Affairs and Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 13, 2015 | D | Notice of Exempt Offering of Securities |
| Mar 16, 2015 | D/A | Filing |
| Aug 5, 2014 | D | Notice of Exempt Offering of Securities |